The Affymetrix GeneChip Scanner 3000,,, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range
The Affymetrix GeneChip Scanner 3000 New Ad... ... ...The Affymetrix GeneChip Scanner 3000 design lays the founda... ...
The Affymetrix GeneChip Scanner 3000
New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range
The Affymetrix GeneChip Scanner 3000 design lays the foundation for continued evolution of the GeneChip platform as an integrated genetic analysis system, supporting continued feature size reduction for higher resolution and greater information content of microarray-based products. The Affymetrix GeneChip Scanner 3000 will seamlessly incorporate future developments as GeneChip technology continues to evolve. In order to address the requirements of new and emerging applications, advancements within the Affymetrix GeneChip system will build upon the GeneChip Scanner 3000. This document will describe the technical aspects of the GeneChip Scanner 3000 and provide details on the innovative technologies used to incorporate advanced design improvements. These advances have resulted in dramatic space savings, increased scan speeds, increased signal resolution, reduced noise, wider dynamic range, and real-time laser monitoring and adjustment.
Previous Scanner System
PRE-OBJECTIVE LINE SCANNING SYSTEM
This technology employs a mirror mounted on the end of a galvanometera limited rotation, oscillating motor. The term pre-objective scanning is derived from the fact that the scanning is accomplished by moving (scanning) the laser beam before a fixed objective lens. The galvanometer enables a laser beam to scan back and forth along a straight-line path, referred to as the excitation line-scan. The excitation linescan, in turn, is directed to, and focused on, the array through a multi-element objective lens located several inches away from the array. Emission is collected by another lens/filter/lens system positioned at an angle to the excitation beam. This
'"/>
Source:
Page: All 1 2 3 4 5 6 7 8 9 10 Related biology technology :1.
Fine Tuning Your Data Analysis:
Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms2.
The New Affymetrix GeneChip Scanner 30003.
GeneChip Sample Cleanup Module for cleanup of cDNA and in vitro
transcribed cRNA4.
New statistical algorithms for Monitoring Gene Expression on GeneChip® Probe Arrays5.
General Notes on Primer Design in PCR*6.
siRNA Design Guidelines7.
Avoid siRNA Design Altogether!8.
Cenix-Designed siRNAs for 95% of Human and Mouse Genomes9.
Designing a Successful qRT-PCR Experiment10.
Designing a Better siRNA11.
Designing Controls for siRNA
Experiments
(Date:11/19/2009)...st people would like to be able to charge their ce...nd not too often. A recent discovery made by UC Sa...sed supercapacitors that could do just this. , ...Letters , Prabhakar Bandaru, a professor in the UC...ing, along with graduate student Mark Hoefer, have...
(Date:11/19/2009)..., SEATTLE, Nov. 19 Om...unaudited financial results for the third quarter ...ed September 30, 2009, Omeros reported a net loss ...o a net loss of $7.4 million, or $2.54 per share, ...nded September 30, 2009, the Company reported a ne...
(Date:11/19/2009)... , ,, BETHESDA, Md., Nov. 19 /PRNewswir...X ), an innovator in biotechnology for diabetes th...consulting services to food, supplement, biotechno... it closed the previously reported $6.3 million re...rs of 2,760,870 shares of its common stock and war...
(Date:11/19/2009)..., BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall/...vator in biotechnology for diabetes therapy, and a...ervices to food, supplement, biotechnology and pha... of Tuesday,s Annual Meeting of Shareholders. ,...ated (Nasdaq: SPEX ) elected the following member...
Breaking Biology Technology:Nanotube defects equal better energy and storage systems 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4...BioTechnology, Inc.,announced today that it has be...wal Small Business Innovation Research (SBIR) gran...ple Sclerosis", from the National,Institute of Neu...onal,Institutes of Health (NIH). Receipt of the en...t of certain research milestones., George (Joe) C...
...c and business development flexibility, TSX Excha...stCall/ - Resverlogix Corp.,("Resverlogix") (TSX:R...llion or approximately 60% of its remaining USD$17...t and CEO of Resverlogix stated, "The,economic env... companies,around the globe. This action limits ou...
...egin after markets close at 2:00 p.m. PT ..., Oct. 15 Masimo Corporation,(Nasdaq: MASI ), th...h-Motion- and-Low-Perfusion pulse oximetry, today ...results for the period ended,September 27, 2008 af..., A conference call to review the results will be...
Other Biology Technology:Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug 2Resverlogix Eliminates Sixty Percent of Remaining Debt 2Masimo to Report Third Quarter 2008 Financial Results on October 27, 2008 2PyAOP from Applied Biosystems
Nunc MicroWell Mini Trays from Invitrogen
E. coli Expression System with Gateway Technology from Invitrogen
GIBCO Leibovitz's L-15 Medium powder from Invitrogen
Biology Products: